2017

Phase III APHINITY study shows Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy

APHINITY study shows Roche’s Perjeta®-based regimen reduced the risk of invasive cancer returning compared to Herceptin® and chemotherapy in HER2-positive early breast cancer

SOLE (Study of Letrozole Extension):A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer

Primary results of LORELEI study presentedat ESMO 2017 Congress

PANACEA study suggests immunotherapy may help to overcome trastuzumab-resistant breast cancer

Ovarian Suppression Reduces Recurrence for Young Breast Cancer Patients